Invivyd (IVVD) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Invivyd (IVVD) has outperformed Sionna Therapeutics (SION) over the past year, losing 61.8% versus a loss of 82.8%. Sionna Therapeutics is the larger company by market cap ($221.2 million vs $212.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | SION |
|---|---|---|
| Share price | $0.7212 | $4.90 |
| Market cap | $212.58M | $221.24M |
| 1-day change | +2.97% | 0.00% |
| YTD return | -70.80% | -88.09% |
| 1-year return | -61.84% | -82.81% |
| 5-year return | -97.78% | — |
| EPS (TTM) | $-0.34 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $54.97 |
| 52-week low | $0.528 | $4.01 |
| Distance from 52-week high | -76.51% | -91.09% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +1286.58% | +328.57% |
| Average volume | 4.90M | 2.19M |
| Shares outstanding | 294.76M | 45.15M |
| Employees | 122 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IVVD has outperformed SION by 21.0 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
IVVD vs SION FAQ
Which is bigger, Invivyd or Sionna Therapeutics?
Sionna Therapeutics (SION) is larger, with a market capitalization of $221.24M compared with $212.58M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or SION?
IVVD returned -61.84% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Sionna Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd and Biotechnology: Pharmaceutical Preparations for Sionna Therapeutics.